Archives: Agenda

Fast, furious or never-ending: case studies on accelerating or unexpectedly inflating Phase IB/II timelines and budgets. A site team perspective

• Emerging trends in early stage Evaluating ex-US strategies
• Observations from Novotech’s early-stage sponsors

• Activities
• Innovations
• International collaborations

• There are many obstacles to running a successful clinical trial – and hospital sites can be one.
• Slow to set up, delays to patient recruitment, or poor data quality?
• TCR-Solutions will share some experience and approaches to troubleshooting these challenges.
• We cannot treat hospital sites like commercial vendors, and we must find a way to work with hospitals to ensure they deliver on time and target.

• New regulations and guidance around running oncology trials in the UK: what do you need to be aware of?
• Running clinical trials in conjunction with the NHS: how to ensure your trial is a success
• Developments in UK cancer research: what’s new in 2025?
• Assessing the impact of political and economic changes on UK oncology trials
• The role of the cancer drug fund in accelerating oncology clinical trials in the UK

• How do we ensure the UK is an attractive location for clinical research
• Navigating new regulations around clinical trials smoothly and successfully
• The impact of artificial intelligence: how far can we expect to move forward in the next 12 months?
• Patient centricity in clinical trials: how can burden be reduced in order to make trials easier for patients to participate in?
• Technological developments in 2025 and beyond: what changes can we expect to see in the next 3-5 years?